Newly diagnosed multiple myeloma: making sense of the menu
| Autor: | Caitlin L, Costello |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Hematology Am Soc Hematol Educ Program |
| ISSN: | 1520-4383 1520-4391 |
| DOI: | 10.1182/hematology.2022000404 |
| Popis: | The development of new drugs and subsequent novel combinations for the treatment of newly diagnosed multiple myeloma (NDMM) has resulted in a plethora of treatment options that can make the choice of initial induction therapy a challenge. A greater understanding of both patient- and disease-specific factors can provide a personalized approach to help design a treatment course. Historically, the choice of an induction regimen has been tethered to an initial impression of transplant eligibility at the time of diagnosis. As more effective and better-tolerated induction regimens have emerged, there has been increasing overlap in the induction strategies used for all patients with NDMM, which increasingly provide the ultimate goal of deep and durable remissions. The current treatment options and strategies for the management of NDMM are evaluated using the best available data to provide a rationale for these decisions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|